7. Barhemsys

FDA Building
FDA approved Barhemsys in February to treat postoperative nausea and vomiting in patients who didn’t respond to treatment with an antiemetic from a different class. (FDA)

Active ingredient: Amisulpride
Disease: Postoperative nausea and vomiting
Peak sales estimate: N/A
Approved: Feb. 27
Company: Acacia Pharma

The scoop: Acacia’s road to approval for nausea and vomiting med Barhemsys (amisulpride) was no easy task after the drugmaker received two complete response letters from the FDA. But after bringing on a new active pharmaceutical ingredient (API) maker to get the drug over the finish line, the FDA finally approved Barhemsys in February to treat postoperative nausea and vomiting in patients who didn’t respond to treatment with an antiemetic from a different class. Acacia received the first FDA letter in 2018 when the agency found fault with Acacia's manufacturer during a preapproval inspection. In May 2019, the FDA said the contractor had not resolved the problems and again sidelined Acacia’s candidate. At that point, the Cambridge, U.K.- and Indianapolis-based biotech moved to get a new contractor certified for the API and then late last year said it was ready to take another shot. – Kyle Blankenship

7. Barhemsys